• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT's Propel study meets endpoint

August 17, 2015 By Fink Densford

Intersect ENT Propel study finds efficacy in frontal sinus surgeryIntersect ENT (NSDQ:XENT) said a new study of its Propel mini steroid-releasing sinus implant used after frontal sinus surgery met the primary endpoint in a clinical trial.

The Propel device is already approved for use in the ethmoid sinuses, behind the bridge of the nose, in conjunction with sinus surgery to treat symptoms of chronic sinusitis, the company said.

The device met its primary efficacy endpoint with a 38% relative reduction in the need for post-operative interventions; device placement was successful in 100% of patients with no device-related adverse events, Intersect ENT said.

“Frontal sinus disease contributes greatly to the debilitating symptoms of chronic sinusitis, including severe headaches, and is known to be the most difficult sinus to manage. These results offer an exciting prospect for this group of patients,” principal investigator Dr. Tim Smith of Oregon Health & Science University said in a press release.

The trial is intended to support an expanded indication for Propel for use in the frontal sinuses located behind the eyebrows, the company said. Intersect ENT said it plans to submit an application for the expanded indication this year.

“We are pleased with the positive outcomes from Progress, which bring us another step closer to broadening access to sustained local steroid delivery to more patients suffering from chronic sinusitis. Our next step will be to compile and submit the results to the FDA this year,” CEO Lisa Earnhardt said in prepared remarks.

According to a letter from Leerink Partner investor Richard Newitter, the Propel mini is already being used off-label for frontal sinus surgeries, and an official indication for the procedure could boost adoption of the device.

Newitter said he estimated a 4-5% penetration of the frontal functional endoscopic sinus surgery market in the 1st year post-approval, or around $1-1.5 million in revenue per quarter with the new indication. Newitter added that the firm believes reimbursement through Medicare will be crucial to in-office adoption.

Shares haven’t budged on the news, however, moving less than 1¢ as of mid-day trading today.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS